MT Newswires56d agoneutral
Pfizer Names Interim Finance Chief as CFO Quits; Drugmaker Affirms Full-Year OutlookPfizer (PFE) named an interim head of finance on Thursday as it announced the departure of Chief Fin
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
383last 24h
2067last 7d
344● bullish (7d)
181● bearish (7d)
204publishers
Stocktwits56d agobearish
PFE Stock Drops 3% On Surprise CFO Exit Despite Reaffirmed 2026 GuidanceIn a filing with the Securities and Exchange Commission, Pfizer said Executive Vice President and Chief Financial Officer Dave Denton notified the company on June 16 that he will step down effective August 15.
GuruFocus.com56d agoneutral
Pfizer Shares Dip 1.5% as CFO Dave Denton Announces ExitCecile Guegan will become interim CFO on Aug. 16 while Pfizer searches for a successor.
GuruFocus.com56d agoneutral
Pfizer CFO Exit Adds PressureDave Denton will leave in August as Pfizer works through its post-COVID reset.
MT Newswires56d agoneutral
Sector Update: Healthcare Stocks Decline Thursday AfternoonHealthcare stocks fell Thursday afternoon with the NYSE Healthcare Index decreasing 0.9% and the Sta
Simply Wall St.56d agoneutral
Pfizer (PFE) Names Cecile Guegan Interim CFO As Dave Denton Prepares To ExitPfizer announced that Chief Financial Officer Dave Denton will leave the company in August to pursue an external opportunity. Senior Vice President Cecile Guegan has been appointed Interim CFO, effective upon Denton’s departure. The change affects Pfizer’s top financial leadership at a time when the company is focused on major pipeline investments and internal changes. For investors watching Pfizer (NYSE:PFE), this shift in financial leadership arrives with the stock trading at $25.92 and...
Yahoo Finance Video56d agoneutralVIDEO
Why Accenture, Pfizer, and Kroger are moving todayMarket Catalyst Host Julie Hyman breaks down today's Trending Tickers, giving us the latest on Accenture (ACN), Pfizer (PFE), and Kroger (KR).
Exec Edge56d agoneutral
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.
Zacks56d agoneutral
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.
InvestorsHub56d agoneutral
Pfizer Shares Slip Following CFO Transition AnnouncementPfizer Inc. (NYSE:PFE) shares edged lower on Thursday after the pharmaceutical giant revealed that Chief Financial Officer Dave Denton will step down from his position and leave the company in August.
Zacks56d agobullish
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract InfectionsGSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
Quartz56d agoneutral
Pfizer CFO Dave Denton stepping down in August 2026Cecile Guegan will serve as interim CFO starting August 16 while Pfizer searches for a permanent replacement
Investing.com56d agobullish
FreeCast surges premarket; Accenture, Novocure slideInvesting.com - U.S. stock futures ticked higher on Thursday, as the signing of an interim Middle East peace deal helped ease concerns sparked by the Federal Reserve’s hawkish policy outlook.
BioPharma Dive56d agobearish
Pfizer CFO to step down; Denali sells a regulatory fast-passA search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid dividends.
CFO Dive56d agoneutral
Pfizer CFO departs for consumer goods sectorDave Denton joined Pfizer in 2022 from Lowe’s Companies and is leaving for an unspecified “professional opportunity” in consumer goods, the company said.
Trefis57d agoneutral
Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That VanishedManagement once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.
Insider Monkey57d agobullish
H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ:GPCR) from $100 to $70, which still leads to an adjusted upside potential of more than 61%. The firm upheld its Buy rating on the […]
Reuters Videos57d agoneutralVIDEO
Big pharma taps UK playbook to pressure Europe on drug prices<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing. </p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers. </p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs. </p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines. </p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up. </p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation. </p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>
Simply Wall St.57d agobullish
Pfizer (PFE) Expands China Partnership With SINOPHARM Around Diflucan And Future LaunchesPfizer and SINOPHARM have entered into a new partnership to promote antifungal drug Diflucan in China. The collaboration also includes plans to work together on future Pfizer product launches in the Chinese market. The agreement focuses on supply chain optimization, resource integration, and improving commercial execution across China. Pfizer (NYSE:PFE) is using this new agreement with SINOPHARM to deepen its presence in one of the world’s most important pharmaceutical markets. With the...
24/7 Wall St.58d agobullish
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes Moderna stock to +94% year to date (YTD), easily the best performance in the major vaccine cohort. By comparison, Pfizer (NYSE:PFE) stock is ... Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
GuruFocus.com58d agoneutral
Novo Nordisk to File Oral Wegovy in ChinaCEO Doustdar expects to submit oral Wegovy for Chinese regulatory approval in "a few months"
GuruFocus.com58d agoneutral
Novo Seeks China Approval for Wegovy PillThe move could expand Novo's reach in a key obesity-drug market.
Zacks58d agoneutral
The Zacks Analyst Blog Highlights Pfizer, Altria, Newmont, Koil Energy and Stratus PropertiesPfizer, Altria, Newmont, Koil Energy and Stratus Properties are featured for their growth drivers, challenges and recent stock performance.
Zacks58d agoneutral
Top Research Reports for Pfizer, Altria & Newmont Corp.Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Altria Group, Inc. (MO) and Newmont Corp. (NEM), as well as two micro-cap stocks, Koil Energy Solutions, Inc. (KLNG) and Stratus Properties Inc. (STRS).
Motley Fool59d agoneutral
Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit GrowthPfizer's business may be in better shape than investors think.
Zacks59d agoneutral
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to KnowPfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.